Glenn Goddard - Sep 7, 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Financial Officer
Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Sep 7, 2021
Transactions value $
-$576,410
Form type
4
Date filed
9/9/2021, 05:38 PM
Previous filing
Sep 1, 2021
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Options Exercise $50.8K +3.48K $14.58 3.48K Sep 7, 2021 Direct
transaction NTLA Common Stock Sale -$627K -3.48K -100% $180.12 0 Sep 7, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Options Exercise $0 -3.48K -21.85% $0.00 12.5K Sep 7, 2021 Common Stock 3.48K $14.58 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.00 to $180.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 7, 2021 at each separate price.
F3 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 11,833 shares as of September 7, 2021.